Shares of the country's leading drug maker - Sun Pharma on Tuesday reported a 13 percent year-on-year (YoY) rise in consolidated net profit to Rs 2,047 crore, compared to Rs 1,813 crore reported in the same quarter in 2020. which was sharply above analysts’ expectations. Strong operating performance and healthy revenue growth supported the bottom line during the quarter. Analysts had expected the company to report a consolidated net profit of Rs 1,698.7 crore and revenues of Rs 9,443.4 crore for the reported quarter. Consolidated revenue came in higher at Rs 9,626 crore for the quarter, compared to Rs 8,553 crore in September 2020 quarter, registering a 12.5 percent growth. Sun Pharma's India sales jumped 26 percent to ₹ 3,187 crores while its sales in the US came in at $361 million, up 8 percent annually. Sun Pharma's EBITDA also known as operating profit came in at ₹ 2,560.8 crores, up 21 percent over Q2 last year, with a resulting EBITDA margin of 26.8 percent.
Read more